Massive Headwinds Are on the Horizon for Pharmaceutical Stocks, but Here Are 2 That Could Weather the Storm

Pharmaceutical companies regularly encounter substantial headwinds. Among the most significant are patent cliffs -- when therapies lose patent exclusivity, inviting cheaper generic or biosimilar competition that erodes their market share. Although these sometimes threaten drugmakers, some can effectively handle the challenge and perform relatively well.With that as a backdrop, let's discuss two pharmaceutical leaders that have faced (or will face) patent expiration for some of their most important products, but should be able to overcome the threat: Johnson & Johnson (NYSE: JNJ) and Novartis (NYSE: NVS).Image source: Getty Images.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool